Domov › Steatotična bolezen jeter › Georgia
Klinične študije za Steatotična bolezen jeter v Georgia
8 študij za Steatotična bolezen jeter išče udeležence na lokacijah v Georgia.
Mesta v Georgia
Uradno besedilo študije (angleško)
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Southeast Clinical Research Center, Dalton
- Teak Research Consults, Lawrenceville
- Gastrointestinal Specialists of Georgia, Marietta
- in še 1
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Atlanta
- Akero Clinical Study Site, Gainesville
- Akero Clinical Study Site, Marietta
Vključevanje udeležencevFaza 3
Starost 18–80 · Vsi spoli · Posodobljeno 21. sep. 2026 · NCT06528314A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- CenExel - iResearch, Decatur
- Gastrointestinal Specialists of Georgia, PC, Marietta
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 9. sep. 2026 · NCT07288138A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Athens
- 89bio Clinical Study Site, Dalton
- 89bio Clinical Study Site, Marietta
Vključevanje udeležencevFaza 3
Starost 18–80 · Vsi spoli · Posodobljeno 3. sep. 2026 · NCT06318169A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Athens
- 89bio Clinical Study Site, Atlanta
Vključevanje udeležencevFaza 3
Starost 18–75 · Vsi spoli · Posodobljeno 3. sep. 2026 · NCT06419374A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
- GSK Investigational Site, Atlanta
Vključevanje udeležencevFaza 2
Starost 18–70 · Vsi spoli · Posodobljeno 3. avg. 2026 · NCT06613698A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Marietta
Vključevanje udeležencevFaza 3
Starost 18–75 · Vsi spoli · Posodobljeno 27. jul. 2026 · NCT07221227A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- GSK Investigational Site, Marietta
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 8. jul. 2026 · NCT06920043Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.